Wednesday, 14 April 2021

DB Life Sciences launches Curol+ to combat air, dust pollution in India

06 April 2021 | News

Curol+ is a liquid-based anti pollution product that aims to 'CURE ALL' dust and air pollution related problems

DB Life Sciences LLP, a wholly-owned subsidiary of The House of Fusion Group, has introduced its revolutionary liquid-based anti pollution product Curol+ in India.  Curol+ is a liquid-based anti pollution product that aims to 'CURE ALL' dust and air pollution related problems.  A game changer in removing the air-borne particles inside the room which carry viruses and infections along the dust mites, it’s has launched 3 different variants:

  • Curol+ Outdoors
  • Curol+ Indoor Hard flooring
  • Curol+ Indoor Carpet

Curol+ transforms the floor into a giant air filter and diminishes dust levels. It works on enhancing the indoor air quality and also refreshing the breathing environment at home, office, industrial and commercial spaces.  The outdoor product reduces PM levels outdoors. The effectiveness is minimum 65 per cent in just seven days of usage.

Speaking on the launch, Dhruv Bhatnagar , CEO , DB Life Sciences LLP, said, “Curol+ delivers powerful chemical-free liquid-based anti-pollution product guarantees minimum reduction of fine particulate air pollution PM 2.5 & PM 10 in one week and is affordable.”

“We are committed to unilaterally support India’s war on air pollution and the National Clean Air Programme (NCAP).  India is a strategic market for us and we have established a manufacturing plant in Gurugram, Haryana, which reaffirms our commitment India’s Vision - ‘Make in India, make for the World,” added  Bhatnagar.

Curol+ DB Life Sciences is developing a real time app provides IoS & Android app which will give users accurate and continuous access to the indoor air quality and other allied parameters at all times as part of a specific package along with the monitor.


× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account

Survey Box

Should we be cautious of viewing COVID-19 vaccine as silver bullet?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls